Sinolink research reports pointed out that the pharmaceutical sector, along with the overall market warming, has seen improved performance in terms of funds, and after entering the window of third quarter report disclosure, the pharmaceutical sector is the most prosperous among listed medical companies, while the prospect of consumer medical reaching the bottom and recovering is also a high probability event. The mid-term investment opportunities in these two areas are worthy of the most attention. In addition, with various national and local group procurement, negotiations, and other clearing activities gradually coming to fruition by the end of the year, the pharmaceutical sector as a whole is expected to have the opportunity for valuation restoration.